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============

Regulating gene expression is a fundamental mechanism used by cells to orchestrate the complex development of all tissues. This multi-tiered event is modulated by many processes including modification of DNA, regulation of pre- and post-transcripts, and protein modifications^[@CR1]--[@CR3]^. Gene regulation at the DNA level occurs through several mechanisms, including chromatin modification directed by DNA methylation, and noncoding RNA (ncRNA) or DNA-binding proteins^[@CR4],\ [@CR5]^. Transcription factors are the main contributors in regulating networks at the transcription level. Additionally, cells regulate how much mRNA is translated into proteins by modulating capping, splicing, addition of a Poly (A) tail, the sequence-specific nuclear export rates, and by sequestering the RNA transcript^[@CR2],\ [@CR6]--[@CR8]^. The translation of mRNA is also controlled by a number of mechanisms at initiation or by mRNA silencing. In the initiation process, recruitment of small ribosomal subunits is modulated by mRNA secondary structure, antisense RNA binding, or protein binding while the translational repression and gene silencing is modulated by microRNAs (miRNAs)^[@CR9]--[@CR11]^. In this study, we discover the synergistic manner in which three modulators (miRNA, nuclear hormone receptors (NHRs), and epigenetic factors) influence the retina in a normal and diseased state.

miRNAs have recently emerged as an important class of post-transcriptional regulatory factors and play a crucial role in regulating gene expression in the retina^[@CR12]--[@CR14]^. miRNA coding sequence typically resides in intergenic regions or on the anti-sense strand of genes^[@CR15],\ [@CR16]^. miRNAs are self-sufficient, retain promoters and regulatory elements, and have the capacity to regulate their own expression. Recent studies revealed that there are more than 400 miRNAs expressed in the retina, and miRNA gene regulation has been shown to affect retinal development, function, and disease^[@CR14],\ [@CR17],\ [@CR18]^. Previous studies have demonstrated significant differences between the expression profiles of miRNAs in the embryonic and adult retina^[@CR18]^. These profiles suggest specific roles for miRNAs in the developing and mature retina. Different groups and clusters of miRNAs have been identified and are usually co-expressed under similar conditions^[@CR19]^. Recent studies also demonstrate that variations in gene expression involving transcription factors or miRNAs are implicated in numerous retinal diseases^[@CR14]^. miRNAs play an important role in the development and maintenance of photoreceptors cells. Therefore, lack or misexpression of miRNAs are associated with diseases such as retinitis pigmentosa, age-related macular degeneration (AMD), light-induced retinal degeneration, and Stargardt disease^[@CR20]--[@CR22]^. Complete loss of the miR-24a, for example, impacts the rate of apoptosis in retinal precursors, leading to a decrease in the size of the eye^[@CR23]^. Global loss of retinal miRNAs by loss of Dicer expression has severe and detrimental effects on retinal development and physiology. Several loss of function studies reveal miRNAs are crucial regulators of differentiation and promote the survival of retinal neuronal progenitors^[@CR14],\ [@CR24],\ [@CR25]^. In addition, altered miRNA expression has been demonstrated in rodent models of Retinitis Pigmentosa (RP), Induced Uveitis, Retinoblastoma, and Diabetic Retinopathy^[@CR26]--[@CR28]^. Consistent with these studies, retinas have a different expression miRNA profile than normal retinas^[@CR29]^. Furthermore, it is increasingly evident that the two classes of gene modulators, transcription factors and miRNAs, work synergistically within given gene networks^[@CR30]--[@CR32]^.

Nuclear hormone receptors (NHRs) are part of a large superfamily of ligand-dependent steroid hormone receptors that often regulate transcription in a ligand-dependent manner and can function as activators or repressors of gene expression. NHRs regulate many biological processes to maintain cellular homeostasis and are significant regulators of retinal development, maintenance, and disease^[@CR33]--[@CR37]^. miRNAs are regulated by nuclear receptors via three main mechanisms: binding to the promoter region, indirect regulation by interacting with nuclear receptor target genes, and regulation of miRNA biogenesis^[@CR38]^. Nuclear receptor class 2, subfamily e, member 3 (Nr2e3) and retinoic acid receptor-related orphan receptor alpha (Rora) are key regulators of retinal development and function^[@CR33],\ [@CR39]--[@CR45]^. Mutations in *NR2E3* are associated with several retinal diseases including enhanced S-cone syndrome, Goldman-Favre Syndrome, Clumped Pigmentary Retinal Degeneration, and Autosomal Recessive and Dominant Retinitis Pigmentosa^[@CR46]^. Mice lacking *Nr2e3*, *Nr2e3* ^*rd7*/*rd7*^, *rd7*, exhibit a slow progressive retinal degeneration, characterized clinically by pan-retinal spotting, and histologically by whorls and rosettes due to excess production of blue opsin expressing cone cells followed by progressive degeneration of both rod and cone photoreceptor cells^[@CR41],\ [@CR47],\ [@CR48]^.

Our prior studies show *Nr2e3* regulates *Rora* ^[@CR42]^ and both are implicated in AMD pathogenesis^[@CR49]--[@CR51]^. RORA is ubiquitously expressed and plays a role in lipid metabolism, bone morphogenesis, and photoreceptor development^[@CR50]^. Studies of the knockout mouse model for *Rora* (Staggerer) show it is highly expressed in cerebellar Purkinje cells, and plays a crucial role in the CNS^[@CR51]^. Staggerer mice are a model for human ataxia characterized by reduced number of Purkinje cells^[@CR52],\ [@CR53]^. In the retina, *Rora* is expressed in the ganglion cell layer and the inner nuclear layer of the adult retina^[@CR54],\ [@CR55]^, and regulates the expression of the cone opsin genes, *Opn1sw* and *Opn1mw* ^[@CR45]^. More recently, our colleagues discovered *Nr2e3* is upregulated in the conditional knockout of epigenetic factor Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit, Ezh2, suggesting a link between *Nr2e3* and epigenetics^[@CR54]^.

In addition to miRNA and NHR regulation, epigenetic events such as DNA methylation and post-translational modifications of the histones regulate gene expression. The marker histone-3, on lysine-27 (H3K27me3), trimethylates histones is a strong epigenetic regulator that serves to silence genes and is regulated by EZH2^[@CR56]^. EZH2 is a subunit of the Polycomb Repressor Complex2 (PRC2) and is involved in the regulation of a key development transcription factor family of genes including homeobox (HOX), SRY box (SOX), paired box (PAX) and wingless type (WNT). EZH2 functions in the PCR2 histone methyltransferase complex involved in the silencing of HOX genes during development^[@CR57]^. In the PCR2 complex, EZH2 acts as a catalytic agent that methylates lysine 9 and 27 in histone H3^[@CR56],\ [@CR58]^. EZH2 as well as other genes from the PCR2 complex induce the overexpression of E2F, a cell cycle regulator, in tumor cell lines^[@CR59]^. EZH2 also interacts with retinoic acid (RA) to induce neural stem cell differentiation^[@CR59]--[@CR61]^. Interestingly, microarray data of *Ezh2* ^*−*/*−*^ retinas detected upregulation of *Nr2e3* consistent with a phenotype of suppression of neural proliferation and differentiation^[@CR62]^. *Ezh2* ^*−*/*−*^ mice exhibit retinal degeneration characterized by functional loss of photoreceptors, detected by loss of scotopic and photopic ERG responses, and histologically by retinal thinning at one month of age.

Macular degeneration is a leading cause of blindness yet there are no known genetic causes, and therapies are not effective on a significant number of patients. It is clear from many studies that gene expression and related disease occur via a dynamic and complex synergistic integration of multiple mechanisms of regulation. In this study, we examine the synergistic modulation of NHRs *Nr2e3* and *Rora*, miRNAs, and the epigenetic factor *Ezh2*. As both *NR2E3* and *RORA* have been implicated in AMD, we evaluated our miRNA potential gene targets as well as differentially expressed genes from each mouse model against gene expression data from a large cohort of AMD patients' donor eyes from unrelated subjects. Lastly, we determined which of these differentially expressed genes and miRNAs are directly regulated by NR2E3 and/or RORA. This is the first comprehensive study to evaluate multiple mechanisms of gene regulation and determine their combined impact on biological pathways and human disease.

Results {#Sec2}
=======

The retina has progressive, dynamic miRNA expression {#Sec3}
----------------------------------------------------

In this study, we employed a comprehensive analysis and filtering strategy to identify key miRNA and their target genes that are differentially expressed in *rd7*, regulated by *Rora*, *Nr2e3*, and *Ezh2*, and implicated in AMD (Fig. [1](#Fig1){ref-type="fig"}). A miRNA microarray analysis was conducted on retinas from *Nr2e3* ^*rd7*/*rd7*^ and control C57BL6/J mice at embryonic (E) 18.5 day and postnatal (P) days 6, 14, and 30 to capture the dynamic changes that occur in a developing retina to its maturity. Differential miRNA expression was observed across multiple time points, (Supplemental Figure [S1](#MOESM1){ref-type="media"}). Interestingly, this heat map shows clear differences in the expression of miRNAs between the embryonic and adult points and postnatal day 6 (P6) illustrates a transition between development and maturity. In the initial analysis and filtering, redundant probes, erroneous control spots, and miRNAs with no known gene targets were removed from analysis and miRNAs differentially expressed in more than one time point were classified as "shared". Using these criteria, 54 miRNAs were differentially expressed between *Nr2e3* ^*rd7*/*rd7*^ and *C57BL6*/*J* mice with a minimum 2-fold change and a p value of p \< 0.001. Of the differentially expressed miRNAs, 37 miRNAs were unique to E18, 4 miRNAs were unique to P6, 3 miRNAs were unique to P14, and 10 miRNAs were shared between embryonic time point and one or multiple postnatal time points (Fig. [2A,B](#Fig2){ref-type="fig"}). Interestingly, while most of the miRNA that were differentially expressed at multiple time points were either consistently increased or decreased, four miRNAS showed altered pattern of expression at each time point they were differentially expressed (Fig. [2C](#Fig2){ref-type="fig"}). Previous studies of miRNA profiles expressed in the embryonic and adult retina were cross-referenced revealing common and unique miRNAs to our study^[@CR17],\ [@CR18]^. Additionally, prior studies from various models of retinal degeneration identified over 300 differentially expressed miRNAs^[@CR63]--[@CR90]^, a total of 16 common miRNAs were identified (miR-1187, miR-125b-5p, miR-331-3p, miR466d-3p, miR-467f, miR-542-3p, miR-574-5p, miR654-3p, miR669h-3p, miR-882, miR-342-3p, miR-466a-5p, miR-466d-5p, miR-706, miR-345-3p, miR532-5p). This study reveals 38 unique miRNAs that may be particular to the Nr2e3 regulated pathway. All 54 differentially expressed miRNAs were subsequently evaluated against the mirBase to determine all potential target genes for each miRNA (Table [1](#Tab1){ref-type="table"}). Each miRNA can have up to 700--1500 potential target genes. Potential miRNA target genes were cross-referenced to previously published microarray expression data (GSE24512) of genes misexpressed in *Nr2e3* ^*rd7*/*rd7*^ retinas at E18 and P30.Figure 1Comprehensive filtering strategy to identify multimodal regulation of miRNAs and their target genes. Step 1. 10 retinas per time point (E18, P6, P14, P30) were collected from B6 and *rd7*. Step 2. miRNA microarray was performed on samples from step 1. 54 differentially miRNAS were identified with 2-fold change, P \< 0.001. Step 3. Subsequent filtering analysis of miRNA expression data was performed using BRB Array Tools along with Stanford Statistical Analysis of Microarrays (SAM) and evaluated using miRBase to identify their potential target genes. Step 4. miRNA targets were then cross-referenced with E18 microarray and P30 *rd7* microarray data. Steps 5, 6. Genes that were found to be statistically significant were analyzed using Ingenuity Pathway analysis to algorithmically generated gene networks in which the default cutoffs identify those genes that were significantly differentially regulated in the network. Step 7. Genes that were identified through the networks were screened for the nuclear receptor-binding site of Nr2e3 and RORA and further analyzed by chromatin immunoprecipitation. A total of 68 genes were direct targets of RORA and/or Nr2e3 as well as 8 miRNAs (out of the 54 differentially expressed miRNAs identified). The results obtained were then cross-referenced to AMD-RNAseq data and microarray data from the epigenetic factor Ezh2. This filtering strategy allowed us to identify 2 genes (Ell2 and Entpd1) as well as 3 miRNAs (mir466, miR1187 and miR710) that are regulated by epigenetic factors and nuclear hormone receptors and are associated with AMD pathogenesis. Figure 2miRNAs differentially expressed between B6 (wildtype) and *rd7* (mutant) retinas. (**A**) miRNAs that are differentially expressed at E18, P6, or P14 (**B**) miRNAs differentially expressed between the embryonic time point and one adult time point, and (**C**) miRNAs differentially expressed in more that one time point and have an alternate pattern of expression. Minimum 2 fold change and P \< 0.001. Table 1miRNAs differentially expressed in *rd7* vs B6 and their potential target genes.Expression TPmiRNATarget GenesE18miR-1187Abcc9, Acpp, B3gnt9, Bnc2, Casp12, Cpm, Crhbp, Dpt, Egfl6, Entpd1, Fndc1, Fras1, Has2, Lcp1, Mylk4, Nox4, Otx1, Papss2, Peg3, Pgm5, Rgs5, Stard8, Stat6, Tek, Tfcp2l1, Vamp5, Wnt4miR-125b-5pAcer2, Atp1b4, Bmf, C77080, Ehd4, Enpep, Ets1, Eva1a, Hapln1, Jade2, Mgll, Msrb3, Rhov, Serpinb5, Snx31, Ucp2miR-188-3pAlcam, Arhgef3, Atp1b4, Cd248, Cxcl12, Egln3, Ell2, Flrt2, Gbp7, Grhl2, Ifi202b, Itgb3, Itpripl2, Msrb3, Muc4, Myot, Scara5, Slc16a12, Smoc2miR-296-3pEpb4.1l1miR-327Abca9, Arhgap36, Col18a1, Crim1, Cspg4, Cxcl12, Entpd1, Fbn2, Iigp1, Kcnq5, Lamp2, Ppfibp2, Ptprb, Ryr1, Thbs1, Tmem88miR-331-3pMgllmiR-342-5pPpargc1amiR-34b-3pFras1miR-362-3pIl13ra1, Mef2c, Ppp1r3b, Prdm16, Sspn, Unc45bmiR-369-3pAfap1l2, Aspn, Mylk4, Sema3d, ShemiR-380-3pDstmiR-423-5pBmf, Ccnd2, Dlk1, Mgll, Myrf, Slc7a8miR-466b-5pAcer2, Fam46a, Ppargc1a, Tbx22miR-466c-5pAcer2, Fam46a, Ppargc1a, Tbx22miR-466d-3pArap2, B3gnt9, Dmrta2, Dsg2, Dst, Ets1, Fam46a, Fgfr2, Gdf10, Jag1, Matn2, Piezo2, Sgms1, Stard8, Tbx22, Tgfbr3miR-466e-5pAbcc9, Acpp, B3gnt9, Bnc2, Casp12, Crhbp, Dpt, Egfl6, Entpd1, Fndc1, Fras1, Has2, Lcp1, Mylk4, Nox4, Otx1, Papss2, Peg3, Pgm5, Rgs5, Stard8, Stat6, Tek, Tfcp2l1, Vamp5, Wnt4miR-466f-5pFzd4miR-467fDmrta2, Fam46a, Fam84a, Fndc1, Hmcn1, Itpripl2, Jag1, Mef2c, Msrb3, Stard8, Tbx22, Tek, Thbs2, Trp63miR-467gArap2, B3gnt9, Dmrta2, Dsg2, Dst, Ets1, Fam46a, Fgfr2, Fgl2, Gdf10, Jag1, Matn2, Piezo2, Sgms1, Stard8, Tbx22, Tgfbr3miR-542-3pCgnl1, Fgl2, Jade2, Lpp, Ppp1r3b, Slc7a8, Sspn, Tgfbr3miR-574-5pAcpp, Fndc1, Mylk4, Ntrk2, Rgs5, VcanmiR-654-3pCd55, Lamc1, Ntrk2, Ppp1r3b, Thbs2miR-666-3pBmp7, C77080, Ets1, Fam174b, Fzd4, Ptgfrn, Rab27amiR-669gNtrk2miR-669h-3pDsc2, Fndc1, Foxc1, Frk, Tbx22miR-669iCd36, Fgl2, Fndc1, Gatm, Tbx22miR-687Crim1, Dsg2, Mfsd7c, Msrb3miR-693-5pEgfl6, Foxc1, Il13ra1, Mef2c, Papss2miR-707EhfmiR-710Dsg2, Jag1, Lpar1, Mef2cmiR-743b-3pAcer2, Afap1l2, Bnc2, Cast, Ell2, Elovl7, Flrt2, Fndc3b, Lpp, Lrig1, Npr3, Ntrk2, Ptgfrn, Scara5, Sema3c, Tgfbr2miR-804B3gnt9, Dpt, Foxc1, Osr1miR-875-3pBnc2, Cd44, Ehf, Fam46a, Fgl2, Frk, Il13ra1, Lamc1, Mef2c, Otx1, Ptgfrn, Rbms1, Sema3c, Sgms2, Sspn, Tfcp2l1miR-878-3pCgnl1, Elk3, Mef2c, Sema3c, Sema3dmiR-878-5pPtprb, TrdnmiR-882Atp1b4, Bmf, Dsc2, Fosl2, Mgll, Ntrk2, Rgs5, Sgms1, Tfcp2l1miR-883a-5pBnc2, Eef2k, Fam174b, Lyz1E18, P6miR-434-3pSulf1E18, P14miR-1192Bmp7, Boc, Ccbe1, Ccnd2, Cd44, Cd55, Col25a1, Dennd2c, Dmp1, Ehf, Ell2, Elovl7, Ets1, Fam101b, Fbn2, Flt1, Fosl2b, Foxc1, Fzd6, Hapln1, Itpripl2, Kdelc2, Lmo7, Lpp, Mef2c, Mylk4, Nrp2, Ntrk2, Pdlim7, Piezo2, Prickle1, Sema3c, Sgms1Sgms2, Slc7a8, Tbx18, Tgfbr3, Thbs2, Trp63, Unc45miR-342-3pNtrk2miR-466a-5pAbcc9, Acpp, B3gnt9, Bnc2, Casp12, Crhbp, Dpt, Egfl6, Entpd1, Fndc1, Fras1, Has2, Lcp1, Mylk4, Nox4, Otx1, Papss2, Peg3, Pgm5, Rgs5, Stard8, Stat6, Tek, Tfcp2l1, Vamp5, Wnt4miR-466d-5pAbcc9, Acpp, B3gnt9, Bmp7, Bnc2, Ccbe1, Cpm, Eef2k, Fam114a1, Fam174b, Fam84a, Has2, Lpp, Msrb3, Nrk, Osr1, Otx1, Papss2, Peg3, Pgm5, Rgs5, Slc7a8, Sspn, Stard8, Stat6, Sulf1, Vamp5, Wnt4miR-706Atp1b4, Dpt, Has2, Il13ra1, Kdelc2, Mef2c, Mylk4, Ostf1, Sema3d, Sgms2E18, P30miR-466f-3pAdora2b, Col25a1, Fam174b, Fam46a, Fam84a, Fbn2, Fndc1, Hmcn1, Itpripl2, Jag1, Lpar1, Macc1, Matn2, Mef2c, Msrb3, Mylk4, Ntrk2, Otx1, Pdgfc, Sspn, Stard8, Tfcp2l1, Thbs2, Trp63E18, P6, P14miR-199a-5pAfap1l2, Cd36, Cgnl1, Ctgf, Ets1, Fzd4, Fzd6, Hapln1, Hmcn1, Itga8, Lamc1, Lrrc173, Matn2, Mertk, Myrf, Ppargc1a, Scara, Sulf1, Zc3hav1E18, P14, P30miR-339-5pKdelc2, Lamc1, Sema3c, Sspn, Tfcp2l1P6miR-345-3pCpm, Eef2kmiR-532-5pAlcam, Ets1, Gbp7, Itpripl2, Lpp, Ppp1r3bmiR-770-3pHapln1, Ucp2miR-673-5pAbca1, Fzd4, Kdelc2, Nrk, Tfcp2l1P6, P14miR-697Lamp2, Flt1, Rbsm1P14miR-129-5pFlt1, Stat6miR-465a-5pAbcc9, Acpp, B3gnt9, Bnc2, Casp12, Crhbp, Dpt, Egfl6, Entpd1, Fndc1, Fras1, Has2, Lcp1, Mylk4, Nox4, Otx1, Papss2, Peg3, Pgm5, Rgs5, Stard8, Stat6, Tek, Tfcp2l1, Vamp5, Wnt4miR-465b-5pAcer2, Fam46a, Ppargc1a, Tbx22Genes identified through microarray data of differentially expressed genes in *rd7* vs B6. Minimum 2 fold change and p \< 0.05.

Identification of microRNA target genes and their gene networks {#Sec4}
---------------------------------------------------------------

Once significantly differentiated miRNA were identified, the analysis focused on miRNAs differentially expressed at embryonic day E18.5 and postnatal day P30.5 for further analysis. These time points were chosen to represent miRNAs important in development when *Nr2e3* is first expressed, and those miRNAs important to maintain normal function in the mature retina. Potential miRNA target genes at each of the two time points were then cross-referenced to microarray expression data^[@CR91]^. To identify differentially expressed miRNA potential target genes showing biological significance, miRNA target genes were cross-referenced with microarray data mentioned above (GSE24512) and those exhibiting greater than 2-fold change of gene expression in *Nr2e3* ^*rd7*/*rd7*^ when compared to *C57BL6*/*J* mice were further analyzed. Duplicate genes (targeted by more than one miRNA within a time point) were counted once in the total number of unique miRNA target genes. This filtering strategy identified over 150 unique genes (Supplemental Table [S1](#MOESM1){ref-type="media"}) which were further analyzed by Ingenuity Pathway Analysis (IPA). IPA analysis revealed eighteen unique gene networks including those for metabolism, development, immune response, cancer, and cellular function (Table [2](#Tab2){ref-type="table"}). These putative miRNA targets are associated with over 50 diseases including diabetes, mellitus, cell proliferation of cancer, neuro-inflammation, apoptosis of neuroblastomas, and heart disease (Table [3](#Tab3){ref-type="table"}). Figure [3](#Fig3){ref-type="fig"} summarizes the combined networks and their common targets and pathways.Figure 3Interacting NR2E3 and RORA Associated Gene Networks. (**A**) IPA analysis of E18 targets identified 9 gene networks with 7 biological classifications. (**B**) IPA analysis of P30 targets identified 9 gene networks with 6 biological classifications. Venn Diagrams show unique and overlapping gene targets of NR2E3 and RORA at E18 and P30. Comparisons of RORA E18/P30 or NR2E3 E18/P30 show less overlap than RORA/NR2E3 at E18 or RORA/NR2E3 at P30. Table 2Ingenuity pathway analysis (IPA) of miRNA, RORA and NR2E3 target genes.E18 Network FunctionGenesCardiovascularANTXR2, ARHGEF3, ASPN, B3GNT9, BMP7, ***CAST***, *DSC2*, **DSG2**, *EGLN3*, *EHF*, ***ELL2***, *ETSS1*, FAM46A, **FGFR2**, FOXC1, **GATM**, GRHL2, HAS2, **JAG1**, LAMC1, LAMP2, LRIG1, ***MGLL***, MUC4, ***NTRK2***, OSR1, PPARGC1A, *PRDM16*, ***PTPRB***, RSPO1, RYR1, ***SEMA3C***, *SEMA3D*, ***SGMS1***, SLC7A8, TGFBR2, TGFBR3, THBS1, THBS2, TRDN, WNT4Immune Response/Injury***CD44***, ***COL18A1***, ***DPT***, **EGFL6**, ELK3, ENTPD1, FGL2, FOSL2, ***FRAS1***, KCNQ5, ***LPP***, LYZ, MYRF, NPR3, OTX1, RAB27A, RGS5, VCANCellular Function***ALCAM***, ARAP2, BACH2, ***BMF***, BNC2, CCND2, **CD36**, CRHBP, CSPG4, DLK1, DST, *ELOVL7*, FLRT2, ***IFI202B***, IL13RA1, *ITGB3*, LCP1, MYLK4, PPFIBP2, ***PPP1R3B***, ***PRDM1***, SCARA5, SGMS2, **SHE**, STAT6, TBX22, TEK, TFCP2L1, UNC45BDevelopmentACER2, *CGNL1*, ***CRIM1***, DMRTA2, *EPB41L1*, **FBN2**, **FNDC3B**, FOXC1, FZD4, GBP7, *JADE2*, **JAG1**, ***LPAR1***, MATN2, MEF2C, ***MSRB3***, MYOT, ***PAPSS2***, PEG3, PGM5, RBSM1, SLC16A12, SMOC2, SSPN, STARD8, TRP63, VAMP5Molecular TransportABCA9, CD248, *FAM174B*, FAM84A, FNDC1, ITPRIPL2, ***LRFN2***, PIEZO2, PRTGMetabolismAFAP1L2, ARHGAP36, CXCL12, EEF2K, **FRK**, *HMCN1*, NOX4, PTGFRNVision***CGNL1***, ***CRIM1***, DMRTA2, *EPB41L1*, **FBN2**, **FNDC3B**, FZD4, KIAA1522, MATN2, ***MSRB3***, ***PAPSS2***, PGM5, RBSM1, SLC16A12, STARD8, VAMP5**PN Network FunctionGenes**Cardiovascular***ARG1***, BACH2, BMP7, **BOC**, **CAV3**, ***CD44***, *COL25A1*, DLK1, ELK3, ETS1, **FLT1**, ***FOXC1***, ***HAPLN1***, HAS2, **JAG1**, *LAMC1*, LCP1, **LPP**, NOX4, NRP2, **NTRK2**, OSTF1, RSPO1, ***SEMA3C***, ***SEMA3D***, SLC7A8, SULF1, TEK, TGFBR3, THBS2, VCAN, WNT4Structure***ABCA1***, ABCC9, B3GNT9, CASP12, *CCBE1*, CCND2, ***CD55***, **CD93**, *EHF*, ***ELL2***, FAM46A, IL13RA1, OSR1, *PPARGC1A*, *PRDM1*, STAT6, UCP2Hematological DiseaseFAM101B, ***FAM114A1***, ***FAM174B***, ***FAM84A***, ***FZD6***, KDELC2, ***MSRB3***, PAPSS2, PDLIM7, PIEZO2, ***PRICKLE1***, SGMS2, TMEM164, VAMP5Cellular FunctionACPP, **DPT**, EEF2K, EGFL6, EHD4, ***ENTPD1***, FOSL2, FRAS1, ***LMO7***, LYZ1, MYRF, OTX1, RGS5, SDPR, TNNT2Immune Response/InjuryASPN, BNC2, *CPM*, DENND2C, ***FBN2***, FIBIN, FNDC1, ITPRIPL2, NEBL, ***PPP1R3B***, STARD8, TBX18MetabolismCRHBP, DEK, DMRTA2, ***FBXL7***, *GATM*, *NRK*, RBSM1, ***SGMS1***, SMPX, TFCP2L1, DST, *ELOVL7*, MYLK4, PGM5, TBX22, UNC45B, SLC7A10DevelopmentACER2, *DSG2*, ***EGFR***, FZD4, LMNA, MEF2C, PEG3, SSPN, TRP63Genes regulated by NR2E3 are in bold; genes regulated by RORA are in italics, and genes regulated by NR2E3 and RORA are bold and italics. Table 3Ingenuity pathway analysis (IPA) of miRNA differentially expressed between *rd7* and B6.miRNADisease AnnotationCancermiR-185-5p, miR-199a-5pEarly invasive cervical squamous cell carcinomamiR-542-3pCell proliferation of bone cancer cell linesmiR-542-3pCell proliferation of ovarian cancer cell linesmiR-542-3pCell proliferation of brain cancer cell linesmiR-125b-5pColony formation of bladder cancer cell linesmiR-125b-5p, miR-185-5p, miR-199a-5p miR-331-3p, miR-542-3pProliferation of tumor cell linesmiR-125b-5pAdvanced Dukes' stage colorectal cancermiR-185-5p, miR-199a-5pProliferation of cervical cancer cell linesmiR-125b-5p, miR-185-5p, miR-199a-5pSquamous-cell carcinomamiR-125b-5pApoptosis of neuroblastoma cellsmiR-125b-5pMetastatic HER2 negative hormone receptormiR-125b-5p, miR-339-5p, miR-542-3pHematologic cancermiR-125b-5pApoptosis of mammary tumor cellsmiR-125b-5p, miR-199a-5p, miR-329-3p miR-331-3p, miR-423-5p, miR-495-3p, miR-542-3p, miR-574-5p, miR-654-3pColorectal cancermiR-185-5pArrest in G1 phase of colon cancer cell linesmiR-185-5p, miR-199a-5pRenal clear cell adenocarcinomamiR-339-5pPrecursor B-cell acute lymphoblastic leukemiamiR-125b-5p, miR-331-3pProliferation of prostate cancer cell linesmiR-125b-5pDifferentiation of embryonic stem cell linesmiR-542-3pCell proliferation of adenocarcinoma cell linesmiR-125b-5p, miR-339-5pLymphoproliferative malignancymiR-199a-5pResponse of endothelial cell linesmiR-125b-5pMigration of microvascular endothelial cellsDiabetesmiR-125b-5p, miR-327, miR-434-3pNon-insulin-dependent diabetes mellitusmiR-125b-5p, miR-185-5p, miR-327 miR-329-3p, miR-434-3pDiabetes mellitusCardiovascularmiR-199a-5p, miR-423-5pFailure of heartmiR-199a-5pInterstitial fibrosis of heartmiR-125b-5p\*, miR-199a-5pFibrosis of heartmiR-199a-5pVasoconstriction of aortamiR-199a-5pEnlargement of heartInflammationmiR-125b-5p, miR-185-5p, miR-188-3p miR-199a-5p, miR-423-5pInflammation of body regionmiR-188-3pInflammation of hippocampusmiR-125b-5p, miR-185-5p, miR-199a-5p miR-423-5pInflammation of body cavitymiR-125b-5p, miR-185-5p, miR-188-3p miR-199a-5p, miR-423-5pInflammation of organmiR-188-3pNeuroinflammationmiR-125b-5pDifferentiation of granulocyte progenitorsmiR-125b-5pTransendothelial migration of monocytesmiR-125b-5pActivation GM-CSF dependent marrow macrophagemiR-125b-5pM1 polarization of M2 macrophagesDiseasemiR-125b-5p, miR-423-5pRapidly progressive idiopathic pulmonary fibrosismiR-125b-5pMyelodysplastic syndrome with 5q- syndromemiR-125b-5pFormation of tubulesmiR-199a-5pChronic hepatitis BmiR-125b-5p, miR-199a-5p, miR-423-5pFibrosismiR-199a-5p, miR-339-5p, miR-495-3pNonobstructive azoospermiamiR-329-3pDent's diseasemiR-125b-5pSystemic sclerosismiR-125b-5p, miR-185-5pChromosomal aberrationmiR-125b-5pAndrogenic alopeciamiR-185-5pDiGeorge syndromeFive major groups with a P value p \< 0.05 were identified with the majority of the miRNAs associated with cancer.

Nr2e3 and Rora co-regulate AMD pathways with miRNAS {#Sec5}
---------------------------------------------------

Previous work from our lab and others has demonstrated that the nuclear hormone receptors *Nr2e3* and *Rora* are key regulators of retinal development and function^[@CR41]--[@CR45]^. To determine which miRNA potential target genes and which miRNAs are directly regulated by NR2E3 or RORA, we scanned approximately 100 kilobases (kb) upstream and into intron 1 of each target gene for putative response element (RE) binding sites. We identified 87 genes and 10 miRNAs that had putative Nr2e3 and/or RORA RE binding sites. Chromatin immunoprecipitation (ChIP) revealed 68 direct target genes of NR2E3 or RORA in the developing (E18) and/or mature retina (P30) (Figs [4](#Fig4){ref-type="fig"}--[6](#Fig6){ref-type="fig"}) as well as 7 miRNAs (Fig. [7](#Fig7){ref-type="fig"}). At E18.5 there were 36 target genes identified for RORA (Fig. [4](#Fig4){ref-type="fig"}) and 32 for NR2E3 (Fig. [5](#Fig5){ref-type="fig"}) with 23 of these genes common targets for both RORA and NR2E3. At P30, we identified 34 RORA targets and 27 NR2E3 target genes, 12 of which were common targets of both (Fig. [6](#Fig6){ref-type="fig"}). In addition, all potential target genes were cross-referenced against an RNA-Seq expression analysis of human macular RPE/choroid and macular retina from an AMD cohort of donor eyes. This cross-reference revealed 145 common genes. In particular, three genes (vascular endothelial growth factor receptor VEGFR1 (*FLT1*), protogenin (*PRTG*), and the synaptic adhesion molecule (*LRFN2*)) were significantly differentially expressed between normal RPE and Neo AMD RPE. *PRTG*, *LRFN2*, and the leucine zipper transcription factor, *BACH2* were significantly differentially expressed between neovascular AMD RPE and intermediate (AREDS3) RPE.Figure 4Chromatin IP (chIP) quantitative real time PCR (chIP-qRT-PCR) of gene targets for RORA at E18. Input (positive control), RORA-chIP, and immunoglobulin G (IgG) negative control. \*Relative expression is calculated as molecules/1000 molecules β-actin. Standard errors are indicated for each gene. All genes had a minimum significance of p \< 0.05. Figure 5Chromatin IP (chIP) quantitative real time PCR (chIP-qRT-PCR) of gene targets for NR2E3 at E18. Input (positive control), NR2E3-chIP, and immunoglobulin G (IgG) negative control. \*Relative expression is calculated as molecules/1000 molecules β-actin. Standard errors are indicated for each gene. All genes had a minimum significance of p \< 0.05. Figure 6Chromatin IP (chIP) quantitative real time PCR (chIP-qRT-PCR) of gene targets for RORA and NR2E3 at P30. Input (positive control), RORA-chIP, NR2E3-chIP, and immunoglobulin G (IgG) negative control. \*Relative expression is calculated as molecules/1000 molecules β-actin. Standard errors are indicated for each gene. All genes had a minimum significance of p \< 0.05. Figure 7Chromatin IP (chIP) quantitative real time PCR (chIP-qRT-PCR) of miRNA targets for RORA and NR2E3 at E18 and P30. (**A**) RORA targeted miRNAs identified at E18 (**B**) NR2E3 targeted miRNAs identified at E18, (**C**) RORA and NR2E3 targeted miRNAs identified at E18. Input (positive control), RORA-chIP, NR2E3-chIP, and immunoglobulin G (IgG) negative control. \*Relative expression is calculated as molecules/1000 molecules β-actin. Standard errors are indicated for each gene. All genes had a minimum significance of p \< 0.05.

Multimodal regulation of AMD gene networks by NRs, miRNAs, and Epigenetic factors {#Sec6}
---------------------------------------------------------------------------------

In addition to NHRs and miRNAs, a key component of gene regulation is epigenetics, and *Nr2e3* has been implicated in the *Ezh2* network^[@CR59]^. In order to determine the epigenetic influence on miRNA and NHR target genes and gene networks potentially regulated by miRNAs and NHRs and associated with AMD. we compared the miRNA target genes against microarray data from P0 *Ezh2* ^*−*/*−*^ retinas as E18 and P0 time points have similar epigenetic effects (personal communication Dr. Chen). Although our studies were performed at E18, mouse gestation is 18--20 days and our prior unpublished work concurred that evaluating gene expression at E18 is quite similar to P0. In this cross-reference, we identified 7 genes and their 13 putative miRNAs as being significantly differentially expressed in *Ezh2* ^*−*/*−*^ compared to normal and also potential target genes of the miRNA identified in this study (Table [4](#Tab4){ref-type="table"}). Furthermore, two of these genes (*Ell2* and *Entpd1*) are commonly modulated by the NHRs *Nr2e3* and *Rora* and are also differentially expressed in the RPE versus retina of AMD cohort.Table 4miRNAs and their potential target genes that are differentially expressed in rd7 vs B6 and Ezh2 vs B6.GenemiRNAExpression TPPgm5***mmu***-***miR***-***466a***-***5p***E18, P6, P14, P30***mmu***-***miR***-***466d***-***5p***E18, P6, P14, P30***mmu***-***miR***-***466e***-***5p***E18, P6, P14, P30***mmu***-***miR***-***1187***E18, P6, P14***Ell2***mmu-miR-1192E18, P6, P14, P30mmu-miR-188-3pE18mmu-miR-743b-3pE18Aspnmmu-miR-369-3pE18, P6, P14**Jag1*mmu***-***miR***-***466f***-***3p***E18, P6, P14, P30*mmu*-*miR*-*467f*E18, P6, P14, P30*mmu*-*miR*-*467g*E18, P6, P14, P30***mmu***-***miR***-***466d***-***3p***E18, P6, P14*mmu*-*miR*-*710*E18, P6, P14Slc16a12mmu-miR-188-3pE18Crhbp***mmu***-***miR***-***466a***-***5p***E18, P6, P14, P30***mmu***-***miR***-***466e***-***5p***E18, P6, P14, P30***mmu***-***miR***-***1187***E18, P6, P14***Entpd1**mmu***-***miR***-***466a***-***5p***E18, P6, P14, P30***mmu***-***miR***-***466e***-***5p***E18, P6, P14, P30mmu-miR-327E18***mmu***-***miR***-***1187***E18, P6, P14Genes and miRNAs regulated by NR2E3 are in bold; genes and miRNAs regulated by RORA are in italics, and genes and miRNAs regulated by NR2E3 and RORA are bold and italics. Minimum 2 fold change and p \< 0.05.

Discussion {#Sec7}
==========

This study is the first to evaluate multimodal regulation of gene expression by evaluating the combined impact of miRNAs, NHRs, and epigenetic factors. Recently, miRNAs have emerged as an important class of regulatory molecules that affect gene expression and in turn normal human development, function, and disease^[@CR15],\ [@CR16]^. miRNAs are endogenous non-coding RNA that regulate gene expression. Approximately 21,264 miRNAs have been identified to date and are classified in families based on sequence or the pre-miRNA structure^[@CR41],\ [@CR48]--[@CR92]^. Over 400 miRNAs have been identified in the retina and function in the similar, parallel biological pathways in different tissues. This study reveals the synergistic impact of miRNAs, NHRs, and epigenetic factors on common biological networks in the normal and diseased state of the retina.

Several studies show that miRNA expression is subject to precise regulation that varies dramatically by cell type, developmental stage, environmental conditions, and disease pathology^[@CR14]^. Currently, over 400 hundred miRNAs have been identified as key modulators of gene expression in the retina^[@CR14],\ [@CR17],\ [@CR93]^. Here, we utilize a comprehensive strategy to identify and characterize multimodal nodes of gene regulation important in human retinal development and disease. We identified miRNAs that, along with the NHRs *Nr2e3* and *Rora* and the epigenetic factor *Ezh2*, play a synergistic role in modulating key biological networks affected in the complex human disease AMD. Eighteen overlapping gene networks were identified at E18 and P30 (Fig. [3A,B](#Fig3){ref-type="fig"}). These networks contained genes that regulate metabolism, immune response, development, and other cellular functions. We identified novel genes that are co-regulated by miRNAs, the nuclear hormone receptors *Nr2e3* and/or *Rora*. When comparing gene targets, NR2E3 and RORA have more targets in common at each time point (E18, 22 genes or P30, 11 genes) than for the same NHR at different time points (Fig. [3A,B](#Fig3){ref-type="fig"}). Furthermore, our study adds novel components to the list of *Nr2e3* and *Rora* targets identified thus far^[@CR42],\ [@CR94]^. We identified 4 miRNAs that are differentially expressed in the retina of affected *Nr2e3* ^*rd7*/*rd7*^ mice. These findings support the hypothesis that genetic variations strongly influence phenotypic outcome by perturbing gene regulation. We discovered 25 unique miRNAs with novel function in the retina. miR-466 and miR-1187, in particular, emerge as significant and regulators, sharing common target genes with *Nr2e3*, *Rora*, *Ezh2* that are also differentially expressed in AMD.

This study revealed several miRNAs and genes functioning in the developmental gene network. miR-466 was discovered in a recent study to identify miRNAs that target the Prospero homeobox 1 (*Prox1*) gene, a known regulator of retinal neurogenesis. More recent studies show *Prox1* influences inflammation-induced lymph-angiogenesis by regulating the expression of VEGF-C receptor. miR-466 in turn impacts lymph-angiogenesis by targeting *Prox1* 3′UTR sequence and suppressing the expression of the gene and therefore reducing lymphangiogenesis^[@CR95]^. miR-1187 has no known function in the retina. Current studies show miR-1187 is down-regulated in a mouse model for acute liver failure and plays a role in hepatocyte apoptosis^[@CR96]^. miR-1187 potential targets include Carboxypeptidase M (*Cpm*) a protein coding gene involved in monocyte and macrophage differentiation^[@CR97]^, Ectonucleoside triphosphate diphosphohydrolase 1 (*Entpd1*) which functions in the hydrolyzes of phosphates into ATP, ADP, and AMP^[@CR98]^, and Fraser extracellular matrix complex subunit 1(*Fras1*) that encodes for an extracellular matrix protein that regulates the epidermal-basement membrane adhesion as well as organogenesis in development^[@CR99]^. *Alcam* codes for a transmembrane glycoprotein that belongs to the immunoglobulin family. *Alcam* has been implicated in the control of numerous developmental and pathological processes such as activation of T cells, melanoma cells, activation of monocytes, and has lately been used as a cancer stem cell marker^[@CR100],\ [@CR101]^. *Alcam* mutant retinas exhibit evaginated or invaginated regions with photoreceptor rosettes that resembled the retinal folds observed in some human retinopathies and also observed in the *Nr2e3* ^*rd7*/*rd7*^ retina^[@CR100]^.

We identified seven putative miRNA target genes whose expression are also regulated by nuclear hormone receptors *Nr2e3*, *Rora*, and *Ezh2*: Phosphoglucomutase 5(*Pgm5*), Elongation factor for RNA polymerase II 2(*Ell2*), Asporin (*Aspn*), Jagged 1 (*Jag1*), and solute carrier family 16 member 12(*Slc16a12*), Corticotropin releasing hormone binding protein(*Crhbp*), Ectonucleoside Triphosphate Diphosphohydrolase (*Entpd1*). *Jag1* is the ubiquitously expressed, well known ligand of Notch and is part of a critical signaling pathway for the development of most tissues^[@CR102]--[@CR104]^. Our results add *Nr2e3* and *Ezh2* to the recently identified regulatory interplay between *Jag1* and 17beta-estradiol that is important in cancer and other tissue specific disorders including retinal diseases^[@CR105]^. *Ell2*, codes for an RNA polymerase elongation factor and helps regulate the activity of the elongation complex. *Ell2* increases the rate of elongation during promoter dependent and independent transcription^[@CR106]^. *Pgm5* is a phosphotransferase involved in the conversion of glucose^[@CR107]^. In contrast the *Aspn* gene is involved in collagen mineralization and helps regulate chondrogenesis^[@CR108]^. *Slc16a12* codes for a transmembrane transporter and plays a role in monocarboxylic acid transport. Mutations in *Slc16a12* are associated with juvenile cataracts^[@CR109]^. Lastly, *Crhbp* is a corticotropin hormone and plays a role in development of the optic cup^[@CR110]^. Our study connects several known, important genes and biological processes with novel miRNAs in normal and diseased retina.

Age-related macular degeneration is a leading cause of blindness in the world. In this study we discovered three key known AMD genes, Fms related tyrosine kinase 1(*Flt1*), the receptor for vascular endothelial growth factor (VEGF) (putative miR1192 target), ATP binding cassette subfamily A member 1 (*Abca1*) (putative miR673-5p target), and Activated leukocyte cell adhesion molecule(*Alcam*) (putative miR188-3p target) are regulated by *Nr2e3* and *Rora* and their potential corresponding miRNAS that are differentially expressed in *Nr2e3* ^*rd7*/*rd7*^ retinas. *Flt1*, a receptor tyrosine kinase, functions in the VEGF pathway, is predominantly expressed in endothelial cells, and is the target for transducing signal in VEGF treatment^[@CR111]^. Moreover, our group previously determined *Flt1* is a target of *Nr2e3*, and demonstrated genetic variants in *Flt1* in four ethnically diverse patient populations associated with AMD^[@CR112]^. *Abca1* is an ATP transporter that is expressed in the retina as well as in the RPE^[@CR113]^. Alleles of the *Abca1* gene are associated with a reduction in the levels of HDL contributing to the formation of drusen accumulation in AMD^[@CR114]^. Variants in *Abca1* have also been shown to be associated with risk of AMD^[@CR115]^. In addition, the miRNAs mir466 and mir1186 have 5 potential target genes that are differentially expressed in AMD patients compared to unaffected individuals: lymphocyte cytosolic protein1 (*Lcp1*), NADPH oxidase 4 (*Nox 4*) regulator of G-protein signaling (*Rgs5*), Dystonin (*Dst*), and *Cpm*.

Recent studies show an important role for the *Nr2e3* in cancer^[@CR116]--[@CR118]^. Interestingly, in this study we identified several miRNAs that are differentially expressed in *rd7* and play a significant role in cancer. The *rd7* model does not develop cancer, however it is well documented that *rd7* mice have a defect in cell proliferation^[@CR41],\ [@CR119]^. Consistent with reports that miRNAs are predominantly downregulated in cancer tumors^[@CR120]^, our studies show that 85% of the miRNAs that are differentially expressed in *rd7* are downregulated. Many of these miRNAs are also subject to epigenetic regulation and are located within CpG islands and regulated by methylation^[@CR121]^. Interestingly, our IPA analysis also revealed the miRNA miR125b-5p is associated with diabetes and cancer (Table [3](#Tab3){ref-type="table"}). A study in breast cancer lines demonstrated a direct link between the methylation status of the cancer miRNA promoters and the development of cancer^[@CR122]^. These findings further substantiate an important role for nuclear receptors such as Nr2e3 in broader-impact diseases such as cancer. Our future studies will further explore the role of Nr2e3 in cancer and regulation of metastasis via miRNAs and NHRs.

While numerous studies show the significant singular impact that NHRs, miRNAs, and epigenetics have on mammalian development and human disease, *in vivo*, the process is dynamic and complex involving multiple factors simultaneously converging for singular biological events. This study is the first to demonstrate the synergistic and combined impact of multiple factors on gene expression in the developing and mature retina and its impact on human disease. While these studies were conducted in the retina, the genes and microRNAs identified here are not unique to the retina or even the CNS. The findings of this study will provide a better understanding of normal development, genomic signatures modulating complex human retinal disease, and valuable tools for better prognostics and development of improved therapies. Future studies will explore developing combination therapies to combat human retinal diseases such as AMD.

Materials and Methods {#Sec8}
=====================

Ethics Statement {#Sec9}
----------------

All animals were bred and maintained under standard conditions at The University of Nebraska Medical Center or Schepens Eye Research Institute research vivarium in accordance with protocol numbers 04086, approved by the Animal Care and Use Committee at the University of Nebraska Medical Center, and 3980417 and 4060617 at Schepens Eye Research Institute. Mice were housed in microisolator cages and provided food and water ad libitum. The University of Nebraska Medical Center is in compliance with the NIH policy on the use of animals in research (Animal Welfare Act P.L. 89--544, as amended by P.L. 91--579 and P.L. 94--279) as well as the Guide for the Care and Use of Laboratory Animals, NIH Publication No. 86--23. All experiments were performed in accordance with relevant guidelines and regulations.

Availability of Data and Materials {#Sec10}
----------------------------------

The miRNA dataset supporting the conclusion of this article has been made MIAME compliant and is publicly available through the Gene Expression Omnibus (GEO) database under the series record GSE91029, and the prior microarray used to cross reference miRNA targets are available under the series record GSE24512. AMD data used as cross reference in this study is in preparation for publication.

Microarray Analysis {#Sec11}
-------------------

MicroRNA microarrays were performed using mirVana 2-color microRNA array chips hybridized to 100 nanogram (ng) of total miRNA from 10 pool retinas for each time point from *Nr2e3* ^*rd7*/*rd7*^ and C57BL6/J (B6) control retinas extracted at E18, P6, P14, or P30. Samples were hybridized to mirVana miRNA chips followed by normalization using Lowess normalization and generation of scatter plots using GenePix to determine the strong data points. Chips were normalized using both whole chip normalization and control spot normalization. Heat map of raw data is found in Supplemental Figure [1](#MOESM1){ref-type="media"}. Differential miRNA expression was determined utilizing a merged data set of both normalization techniques and the following criteria: (1) \>20% spots showing \>2-fold change; (2) P \< 0.001 for log-ratio variation; (3) exclusion of array spots with \>50% missing values. Additional analysis of differentially expressed miRNAs was performed using BRB Array Tools for Excel, as well as the Stanford Statistical Analysis of Microarrays (SAM) plug-in for Excel. miRNA expression data were input into SAM using a false discovery rate (FDR) of \<0.05. Heat map for the microarray analysis with a hierarchical cluster analysis has been previously published^[@CR91]^. Heat map depicting differential expression of miRNA as observed by miRNA array. Values represent median intensity values for the respective label (cy5/cy3). Color-coding of heat map is relative to percentile higher expression values represented in orange and lower expression values in dark indigo (Supplemental Figure [1](#MOESM1){ref-type="media"}). All differentially expressed miRNAs were subsequently evaluated against the mirBase to determine all potential target genes for each miRNA. Each miRNA can have up to 700--1500 potential target genes.

A cross-comparison was made between the miRNA array data (differentially expressed miRNAs) with microarray data (gene expression \>2 fold change). RNA was isolated at E18.5, P6, P14, and P30 from *Nr2e3* ^*rd7*/*rd7*^ retinas as previously described^[@CR42]^. Eyes were enucleated from 7 different animals (at each time point) and placed in phosphate buffered saline (PBS) on ice. Retinas were dissected using a stereomicroscope (Zeiss SV11) and RNA was isolated by TRIzol® extraction. RNA was hybridized to Mouse 420A 2.0 (Affymetrix, Santa Clara, CA) chips by the UNMC Microarray Core Facility according to manufacturer specifications (Affymetrix, Santa Clara, CA). Data quality was assessed using the affyPLM package for the R programming language. Consistency of expression levels was confirmed by validation across multiple redundant probe sets. Differential expression analysis was performed using the Linear Models for Microarray Analysis portion of Bioconductor. Genes found to be differentially expressed for each pair wise comparison using an FDR-adjusted p-value of 0.001 and at least a 2-fold change were combined and used to perform clustering analysis. A self-organizing map (SOM) clustering algorithm was applied to genes showing significant expression differences as judged by mean log2 intensity per strain. The gap statistic was used to estimate the optimal number of clusters.

Quantitative RT-PCR {#Sec12}
-------------------

Each gene and miRNA identified through microarray studies were validated through quantitative real-time PCR (qRT-PCR). Real time PCR was performed as previously described^[@CR42]^ to confirm differential expression observed in the microarray data. RNA was isolated using the samples from the microarray analysis as well as additional individual samples from mice for each strain (total n = 7 per sample type). Two µg of total RNA was reverse transcribed using Retroscript (Ambion). The cDNA samples were diluted 1:100 and real time PCR was performed in triplicates for each primer using Sybr Green PCR master mix (Thermo fisher). Reactions were quantified using an ABI Step One Plus Real Time PCR and analyzed with the corresponding software. Relative expression levels were determined by normalizing cycle thresholds values to the amount of β-actin expressed (1000/2\^Ct gene − Ct β-actin) Statistical significance of differential expression was assessed using a T-test and p \< 0.05.

Pathway Generation and Analysis {#Sec13}
-------------------------------

miRNA and microarray target genes were analyzed using Ingenuity Pathway Analysis (IPA, Ingenuity Systems, [www.ingenuity.com](http://www.ingenuity.com)). Gene identifiers and statistically significant expression values were uploaded into Ingenuity. Default cutoffs were set to identify genes whose expression was significantly differentially regulated and overlaid onto a global molecular network developed from information contained in the Ingenuity Pathways Knowledge Base. Networks were algorithmically generated based on their connectivity. Genes or gene products in the networks are represented as nodes, and the biological relationship between two nodes is represented as an edge (line). All edges are supported by at least 1 reference from the literature, from a textbook, or from canonical information stored in the Ingenuity Pathways Knowledge Base. Nodes are displayed using various shapes that represent the functional class of the gene product.

Chromatin Immunoprecipitation {#Sec14}
-----------------------------

Putative miRNA target genes were analyzed for nuclear receptor binding sites using: 1) classic binding sites of *Nr2e3* (AAGTCA~(n1-4)~AAGTCA) or *Rora* (\[AGT\]\[TA\]\[AT\]\[TA\]C\[AT\]AGGTCA); 2) general nuclear hormone receptor response elements as determined algorithmically by NUBIscan^[@CR123]^. Binding sites were selected at a maximum of 100 kilobases (kb) upstream of each gene's start site to intron 1. Chromatin immunoprecipitation was performed as described previously^[@CR42]^. Briefly, retinas were dissected from P30 C57Bl/6J mice. A total of 8--10 retinas were used per Chip reaction and placed into 400 uL of a PI solution (phosphate buffered saline (PBS) and protease inhibitor cocktail from Roche). Chilled tissue was dissociated and homogenized and cross-linked in 37% formaldehyde for a period of 60 minutes at room temperature in a rotating platform. 1 M glycine was added (final concentration 0.125 mM) and later rinsed with the phosphatase inhibitor (PI) solution in PBS (Thermo, cat\#78430). Sonication was performed using a Qsonica Ultrasonic Processor amplitude 50%, 10 pulses x 30 with 1-second pauses between pulses. Immunoprecipitation was performed overnight using 1 μg of NR2E3 antibody at 4 °C on a rotating platform. The NR2E3 antibody used in this experiment had been previously generated in the laboratory^[@CR43]^ and validated^[@CR42]^. For a negative control goat IgG antibody was used and the input (control) was not incubated with antibody. Immunoprecipitated samples were resuspended with Protein G dynabeads (Invitrogen, cat\#10003D) and a series of washes using wash buffer \#1 (Tris, EDTA 0.5 M, Triton, NaCl 5 M) and wash buffer \#2 (Tris, EDTA 0.5 M, NP-40, LiCl) were performed at room temperature. Samples were reversed cross-inked with NaCl (200 mM final concentration). Quantitative RT-PCR was performed using 1 ul of 1:100 dilution (input) and 1:10 dilution (samples and immunoglobulin G (IgG) control) using conditions described previously^[@CR36]^. All sample data was normalized to IgG control.

Comparison to Human RNA-Seq Data {#Sec15}
--------------------------------

Resulting mouse data was compared to differentially expressed genes found in the Utah human donor eye AMD repository and RNA-Seq dataset (personal communication DeAngelis lab) from macular neural retina and macular RPE/choroid. Cohort is comprised of Caucasians over the age of 60 including representatives of both intermediate and neovascular subtypes with age matched controls.
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